Datopotamab deruxtecan Daiichi Sankyo
Analogs of Datopotamab deruxtecan Daiichi Sankyo
Find cheaper analogs and generic equivalents for Datopotamab deruxtecan Daiichi Sankyo.
Active Ingredient: datopotamab deruxtecan
Product Overview
About Datopotamab deruxtecan Daiichi Sankyo
Datopotamab deruxtecan Daiichi Sankyo was intended for the treatment of adults with non-squamous NSCLC in adults who require systemic therapy (treatment with medicines affecting the whole body as opposed to surgery or radiotherapy). It was to be used in patients with particular genetic changes who had previously been treated with platinum-based chemotherapy and another cancer medicine targeting the cancer’s specific genetic change. It was also to be used in patients without particular genetic changes who had previously been treated with platinum-based chemotherapy and a cancer medicine called a PD-1 or PD-L1 inhibitor. Datopotamab deruxtecan Daiichi Sankyo contains the active substance datopotamab deruxtecan and was to be available as a solution for infusion. Datopotamab deruxtecan has received a positive recommendation by EMA for the treatment of breast cancer. This medicine was originally known as Datopotamab deruxtecan Daiichi Sankyo but later renamed as Datroway.
What it is used for
Datopotamab deruxtecan Daiichi Sankyo was intended for the treatment of adults with non-squamous NSCLC in adults who require systemic therapy (treatment with medicines affecting the whole body as opposed to surgery or radiotherapy). It was to be used in patients with particular genetic changes who had previously been treated with platinum-based chemotherapy and another cancer medicine targeting the cancer’s specific genetic change. It was also to be used in patients without particular genetic changes who had previously been treated with platinum-based chemotherapy and a cancer medicine called a PD-1 or PD-L1 inhibitor.
How it is used
Not available in this source.
How it works
The active substance in Datopotamab deruxtecan Daiichi Sankyo, datopotamab deruxtecan, is made up of two active components that are linked together: datopotamab is a monoclonal antibody (a type of protein) that has been designed to attach to a protein called TROP2. TROP2 is present at high levels on the surface of NSCLC cells; deruxtecan is a toxic substance that kills cells when they divide and grow. It becomes active once datopotamab has attached to TROP2 and enters the cancer cell. Deruxtecan blocks an enzyme called topoisomerase I which is involved in copying the cell DNA needed to make new cells. When topoisomerase I is blocked, cancer cells cannot multiply and eventually die.
Active substance: datopotamab deruxtecan
Visitor ratings
Help others by rating how useful this product page is.
No ratings yet — be the first.